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Abstract: Acute myeloid leukemia (AML) clinical settings cannot do without molecular testing
to confirm or rule out predictive biomarkers for prognostic stratification, in order to initiate or
withhold targeted therapy. Next generation sequencing offers the advantage of the simultaneous
investigation of numerous genes, but these methods remain expensive and time consuming. In this
context, we present a nanopore-based assay for rapid (24 h) sequencing of six genes (NPM1, FLT3,
CEBPA, TP53, IDH1 and IDH2) that are recurrently mutated in AML. The study included 22 AML
patients at diagnosis; all data were compared with the results of S5 sequencing, and discordant
variants were validated by Sanger sequencing. Nanopore approach showed substantial advantages
in terms of speed and low cost. Furthermore, the ability to generate long reads allows a more
accurate detection of longer FLT3 internal tandem duplications and phasing double CEBPA mutations.
In conclusion, we propose a cheap, rapid workflow that can potentially enable all basic molecular
biology laboratories to perform detailed targeted gene sequencing analysis in AML patients, in order
to define their prognosis and the appropriate treatment.
Keywords: nanopore targeted sequencing; acute myeloid leukemia; mutational analysis; FLT3
internal tandem duplications; biallelic CEBPA mutations
1. Introduction
Acute myeloid leukemia (AML) is a molecularly heterogeneous hematological malignancy with
a variable prognosis and response to treatment [1,2]. Recurring molecular lesions identify AML
patient subgroups with different survival probabilities; in fact, results from nucleophosmin 1 (NPM1),
Fms-like tyrosine kinase 3 (FLT3), CCAAT/enhancer binding protein α (CEBPA) and tumor protein p53 (TP53)
mutational screening genes have led to recommendations from the European LeukemiaNet Group that
these be tested in routine practice [3]. Moreover, since the United States Food and Drug Administration
(FDA) approval of targeted inhibitors for FLT3, isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) gene
mutations, predictive biomarkers are also now needed to select AML patients for targeted therapy [4–6].
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Therefore, in AML clinical settings, molecular testing is a requisite in laboratories to confirm or
rule out predictive biomarkers, in order to initiate or withhold targeted therapy, or to enroll patients in
specific clinical trials once their prognostic risk has been defined. In this context, assays performed
by massive parallel next-generation sequencing (NGS) offer substantial advantages in the form of a
simultaneous investigation of numerous genes. However, the cost of NGS-based methods is still high,
in terms of both capital expenses and expertise. Moreover, NGS turnaround time is also quite long,
reaching up to 7 days. In fact, depending on the type of test and the instrument used, the assay time is
contingent on library preparation, sequencing and downstream analysis, but it may be further prolonged
by the need to batch samples so as to reduce costs and workload. New sequencing platforms, such as the
Oxford Nanopore MinION system, offer the possibility of rapid sequencing and immediate availability
of data for analyses. Nanopore sequencing is characterized by long reads and real-time data generation,
features that make it an ideal tool for targeted genes sequencing [7]. MinION has already been
successfully used by our group to detect mutations of the TP53 and ABL1 genes in chronic lymphocytic
leukemia (CLL) and in chronic myeloid leukemia (CML) patients, respectively [8–10]. Moreover,
we recently described the development of a customized, MinION-based gene panel for the targeted
sequencing of genes recurrently mutated in CLL, demonstrating a satisfactory performance [11].
Herein, we describe a nanopore-based assay for the rapid sequencing of six genes (NPM1, FLT3,
CEBPA, TP53, IDH1 and IDH2) that are recurrently mutated in AML. NGS blinded gene analysis was
performed on the specimens collected.
2. Materials and Methods
2.1. Patients
Twenty-two acute myeloid leukemia (AML) patients were included in this study (Table S1).
Molecular evaluation [i.e., NPM1 (A or B mutations) and FLT3 internal tandem duplications (ITD)
or tyrosine kinase domain (TKD) mutations] was performed at diagnosis in all cases. Among them,
we selected five patients (AML#18-AML#22) harboring a complex karyotype, in an effort to increase
the chances of finding cases with the TP53 gene mutations, in accordance with what has already been
reported [12]. No data were available in our series for the CEBPA, IDH1 and IDH2 gene mutational
status. In all the AML cases included in this work, recurrent chromosomal rearrangement was excluded
by molecular and fluorescence in situ hybridization experiments with specific bacterial artificial clones,
as previously described [13–16]. The AML cases were subdivided into two groups, and for the
purposes of the barcoding process, each group had to include no more than 12 samples. Therefore,
each group consisted of 11 cases (AML#1–AML#11 in the first and AML#12–AML#22 in the second) and
one negative healthy control sample (NC) (Human CEPH Genomic DNA Control by Thermo Fisher
Scientific Waltham, MA, USA). Genomic DNA (gDNA) was extracted from bone marrow mononuclear
cells, isolated by Ficoll density centrifugation, using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden,
Germany) and quantified with the Qubit 2.0 Fluorometer (Life Technologies Carlsbad, CA, USA).
The study was approved by the local ethics committee “Azienda Ospedaliero Universitaria Policlinico
di Bari” No. 624 from 21 May 2010. Written, informed consent was obtained from all patients before
enrolment in accordance with the Declaration of Helsinki. AML patient records/information were
anonymized and deidentified prior to analysis.
2.2. Acute Myeloid Leukemia Panel Design and Testing
Our customized AML gene panel for MinION included the known mutation hotspots of NPM1
(exon 11), FLT3 (exons 14,15,20), IDH1 (exon 4) and IDH2 (exon 4); CEBPA (full gene) and TP53 (exons 2–11).
To enrich these genomic regions, we adopted a polymerase chain reaction (PCR)-based strategy using a
combination of primers selected from a larger customized AML panel, designed with the Ion AmpliSeq
Designer tool (Thermo Fisher Scientific), used for data validation.
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Overall, 10 pairs of primers were selected for the target genes and analyzed with the Multiplex
2.1 tool (http://bioinfo.ebc.ee/multiplx) to evaluate primers’ compatibility and find the best primers
pooling solution. In detail, we chose to consider any primer–primer interactions and to pull in the
same group amplicons with a maximum length difference of 400 bps. Three primers pools were thus
identified: pool 1 included primers for CEBPA exon 1, TP53 exons 7–9 and TP53 exons 10–11. Pool 2 was
assembled with primers for NPM1 exon 11, FLT3 exons 14–15, FLT3 exon 20 and IDH2 exon 4. Finally,
pool 3 included primers for TP53 exons 2–4, TP53 exons 5–6 and IDH1 exon 4. The total panel size was
about 7 kb. Table 1 shows the composition of the three primer pools, the respective amplicon sizes and
the primers sequences.
2.3. Multiplex Long-Polymerase Chain Reaction
For each sample, three multiplex long-PCRs were performed using the PrimeSTAR GXL DNA
Polymerase (Takara Bio Inc., Shiga, Japan), 100 ng of gDNA, in a final volume of 50 µL. Thermal-cycling
conditions were 98 ◦C for 10 s, 55 ◦C for 15 s, 68 ◦C for 90 s (30 cycles) and 4 ◦C hold for pool 1;
98 ◦C for 10 s, 60 ◦C for 15 s, 68 ◦C for 60 s (30 cycles) and 4 ◦C hold for pool 2 and pool 3. The PCR
products were visualized by SYBR Safe on an agarose-gel. Since two amplicons in pool 2 had a very
similar size of about 220 bps and were not easily distinguishable by 2.2% agarose gel electrophoresis,
a restriction enzyme digestion of these critical amplicons was made, and the EcoRV-HF restriction
enzyme (20,000 units/Ml; New England BioLabs Inc., Ipswich, MA, USA) was finally selected to verify
their successful amplification and to discriminate them. Twenty uL of the primer pool 2 PCR products
were incubated with 20 units of EcoRV-HF in CutSmart Buffer for 1 h at 37 ◦C. Digestion products
were loaded on a 2.2% agarose gel. To equalize the amount of amplicons contained in each pool,
we evaluated the intensity of bands visualized by SYBR Safe on agarose gel. In detail, we increased by
four-fold the concentration of the primers for NPM1 exon 11 and FLT3 exon 20 in pool 2 and halved
the concentration of the primers for TP53 exon 2–4 in pool 3. The PCR products were purified using
the QIAquick PCR Purification Kit (Qiagen). Before starting library preparation, we quantified and
estimated the purity of samples (Nanodrop, Thermo Fisher Scientific). Equimolar amounts of the three
PCR products (calculated on the average length of the amplicons for each pool) were mixed.
2.4. MinION Sequencing (MS)
According to the 2D Native barcoding genomic DNA (SQK-LSK 208) protocol, a total volume
of 25 uL, containing 500 ng of the amplicons, was end-prepared using the NEBNext Ultra II
End Repair/dA-Tailing Module (New England Biolabs Inc.) and barcoded with the ligation of
nanopore-specific Native Barcodes (NB01-NB12) using Blunt/TA Ligase Master Mix (New England
Biolabs Inc.). Equimolar amounts of each barcoded amplicon were then pulled. According to the
Ligation Sequencing Kit 1D (SQK-LSK108) protocol, a total volume of 50 uL containing 700 ng of the
barcoded amplicons was prepared for sequencing. After the Platform QC run and the priming of the
flowcell, the sequencing mix was loaded and the NC_48Hr_sequencing_FLO-MIN107_SQK-LSK108
protocol was started (MinIONflowcell: FLO-MIN107).
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Table 1. Composition of the three pools of the customized acute myeloid leukemia (AML) gene panel, with the genomic region covered, the primer sequences and the
size of the corresponding amplicons. For each amplicon, the error rate analysis of MinION sequencing data is shown.
Pool Target Genomic Region Length(bp) Primers
Identical Bases Per
100 Aligned Bases
Inserted Bases Per
100 Aligned Bases
Deleted Bases Per
100 Aligned Bases
Substitutions Per
100 Aligned Bases
1
CEBPA exon 1 chr19:33792118-33793481 1363 5
′-GGAGGCACCGGAATCTCCTA-3′
5′-GGCCTGCCGGGTATAAAAGCTG-3′ 86% 2.9% 5.6% 5.4%
TP53 exons 7–9 chr17:7576463-7577667 1204 5
′-CAGGCTAGGCTAAGCTATGATGTTCCTTAGA-3′
5′-CTTGCCACAGGTCTCCCCAAGG-3′ 87.8% 2.5% 5.6% 4%
TP53
exons 10–11 chr17:7572810-7574095 1285
5′-GTGCTTCTGACGCACACCTATTG-3′
5′-AACCATCTTTTAACTCAGGTACTGTGT-3′ 87.5% 2.5% 5.9% 4.1%
2
NPM1
exon 11 chr5:170837410-170837635 225
5′-GTTAACTCTCTGGTGGTAGAATGAAAAATAGA-3′
5′-GATATCAACTGTTACAGAAATGAAATAAGACG-3′ 89.3% 2.4% 5.4% 2.9%
FLT3
exons 14–15 chr13:28607916-28608407 491
5′-GGCAAACAGTAACCATTAAAAGGATGG-3′
5′-TTCCTCTATCTGCAGAACTGCCTA-3′ 88.5% 3.3% 4.6% 3.6%
FLT3
exon 20 chr13:28592521-28592740 219
5′-CACAGTGAGTGCAGTTGTTTACCA-3′
5′-GTCATTCTTGACAGTGTGTTCACAG-3′ 90.2% 2.7% 3.4% 3.7%
IDH2
exon 4 chr15:90631713-90632029 316
5′-CACAAAGTCTGTGGCCTTGTACT-3′
5′-GTTGAAAGATGGCGGCTGCA-3′ 88.8% 2.3% 5.4% 3.6%
3
TP53
exons 2–4 chr17:7579204-7579986 782
5′-GAAGCCAAAGGGTGAAGAGGAATCCC-3′
5′-AGGGTTGGAAGTGTCTCATGCTGGA-3′ 86.4% 2.2% 7.3% 4%
TP53
exons 5–6 chr17:7578016-7578702 686
5′-TTCAACTGTGCAATAGTTAAACCCAT-3′
5′-CTGAGGTGTAGACGCCAACTCTC-3′ 87.9% 2.6% 5.2% 4.2%
IDH1
exon 4 chr2:209113021-209113452 431
5′-ATACAAGTTGGAAATTTCTGGGCCAT-3′
5′-CACTGCAGTTGTAGGTTATAACTATCCA-3′ 88.9% 2.3% 4.8% 3.7%
Mean 88.1% 2.6% 5.3% 3.9%
Genes 2019, 10, 1026 5 of 16
2.5. MinION Sequencing Data Analysis
The fast5 files resulting from the sequencing were uploaded in Albacore (v.2.3.3) for base-calling
and demultiplexing. The NanoOK tool (stable version) was employed for coverage and error
assessment, using the FASTA sequences of the target amplicons as reference. Reads were aligned
on the GRCh37 human reference genome with the BWA–MEM method [17] using specific Nanopore
platform parameters and visualized with the Integrative Genomics Viewer (IGV) browser [18].
For each patient, variant calling was performed with the Somatic Mutation Calling tool, Varscan 2.4.3
(https://github.com/dkoboldt/varscan/). The ‘SNV’ (single-nucleotide variant) and ‘INDEL’
(insertion-deletion) files were filtered as reported below. Data were then annotated for refGene, exac03,
avsnp150 and cosmic81 databases using Annovar software tool (http://annovar.openbioinformatics.
org/en/latest/) and filtered for exonic/intronic position and mutation effect. All results from MinION
Sequencing (MS) were finally compared with the results from S5 sequencing, (S5S) and discordant
variants were validated by Sanger Sequencing (SS).
To detect samples with FLT3 ITD from MS we used the specific tool, Sniffles [19]. The samples
that were positive for the ITD were further analyzed to extract the consensus sequences of the tandem
repeat. The FASTA sequences of the reads mapping on the FLT3 ITD region were extracted from
the bam files and were used to assemble the ITD sequence using the CAP3 [20] algorithm, that
produced some consensus sequences. All consensus sequences were then multialigned together with
the reference sequence. At the end, the inserted repeats were easily detected from the multialignment
file. The complete pipeline with command lines and parameters is reported in File S1.
For the AML cases harboring two CEBPA mutations each, the reads covering the whole genomic
interval between the CEBPA variants identified and without any mismatches or deletions in the
genomic sequences flanking these variants, were filtered with “samtools view” command and samjs
tool (Jvarkit) and used for phasing. From these filtered BAM files, the reads with the SNV/small
INDELs called were selected with the “samtools view” command, whereas the VariantBam tool was
applied to operate a less stringent selection of the reads harboring the larger CEBPA INDEL identified.
The resulting filtered bam files were visualized in the IGV software. From the corresponding SAM
files, the identifiers of the reads supporting each CEBPA mutation were retrieved, and the two lists
of reads were compared in a Venn diagram, in order to establish the relationship between the two
CEBPA mutations.
MinION Sequencing data analysis was conducted on Intel® CoreTM i7-7700K CPU @ 420GHz
RAM16GB IO Unity SSD 1TB (ASUS, Beitou District, Taipei, Taiwan).
2.6. S5 Sequencing (S5S)
Ten ng of the same samples used for MS were analyzed by S5S. A customized panel, encompassing
the full coding regions or specific exons of 26 target genes involved in the pathogenesis of myeloid
malignancies pathogenesis, was used; library preparation and data analysis were performed as
previously reported [21]. The data analysis was focused only on the genomic regions included in our
customized panel used for MS. The choice of the S5S strategy derives from the need to compare MS
results with a conventional NGS approach. However, it must be specified that the two platforms differ,
not only for the sequencing technology (nanopore-based for MinION and semiconductor-based for S5),
but also for the library preparation chemistry: direct amplicon sequencing vs. clonal amplification by
emulsion-PCR and direct DNA strands reading vs. sequencing by synthesis, respectively.
2.7. Sanger Sequencing (SS)
For SS, we performed a PCR target enrichment of the genomic regions for which MS and S5S
produced discordant results. For FLT3 ITD gene analysis, we used Platinum Taq DNA Polymerase
(Invitrogen, Carlsbad, CA, USA), with 200 ng of gDNA, two primers as previously described [22],
in a final volume of 50 uL. Thermal cycling conditions were: an initial denaturation of 95 ◦C for
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3 min, 95 ◦C for 30 s, 62 ◦C for 30 s, 72 ◦C for 30 s (35 cycles), 72 ◦C for 5 min and 4 ◦C hold.
For TP53 we used the International Agency for Research on Cancer (IARC) protocol (http://p53.iarc.fr/).
For CEBPA we used PrimeSTAR GXL DNA Polymerase (Takara Bio Inc.), 100 ng of gDNA, two primers
(CEBPA_179F:CGTCCATCGACATCAGCGCCTA,CEBPA_521R: GCCAGCTGCTTGGCTTCATCCT )
in a final volume of 50 µL. Thermal-cycling conditions were 98 ◦C for 10 s, 55 ◦C for 15 s, 68 ◦C for
1 min (30 cycles) and 4 ◦C hold. The PCR products were visualized on a 2% agarose gel, the bands
were sliced, purified using the QIAquick PCR Purification Kit (Qiagen), quantified with a Qubit 2.0
fluorometer (Life Technologies) and prepared for SS. Electropherograms were then analyzed by visual
inspection with the FinchTV software (v.1.4.0; Informer Technologies, Inc.). For the FLT3 ITD analysis,
we used the tool Indigo.
2.8. Data Availability
The sequence data from this study have been submitted to the National Center for Biotechnology
Information (NCBI) Short Read Archive (https://www.ncbi.nlm.nih.gov/sra/) under accession
Number PRJNA527949.
3. Results
3.1. MinION Sequencing Performance Evaluation
In 24 h from sample collection (cell separation and gDNA extraction: 2 h, multiplex long-PCR and
library preparation: 4 h, sequencing run: up to 16 h or overnight, data analysis: 2 h) the results from
MS were obtained (Figure 1).
Figure 1. Schematic workflow implemented for MinION sequencing approach.
Two MS runs were performed, employing two libraries of 11 patients plus an NC for each and
two different flowcells, with 1085 and 1006 active pores, respectively. A total of 4,556,387 fast5 files
containing raw electric signals was produced. The fast5 files were uploaded in Albacore for base-calling
and demultiplexing, producing about 1.2 Gb. Finally, of the total reads produced, 1,280,642 had a
recognizable barcode. The mean reads length was 950 bp, corresponding to the expected amplicons
size. NanoOK analysis was performed to calculate the error rate for each amplicon. Table 1 shows the
mean values of identity per 100 aligned bases and the mean error rate for insertions, deletions and
Genes 2019, 10, 1026 7 of 16
substitutions for each amplicon. As observed, separate error rate analysis for insertions, deletions
and substitutions revealed higher error values for deletions, in line with historically known nanopore
error rate data [23–25]. Coverage analysis showed that all genomic regions included in our gene panel
were completely covered in each sample. As reported in Table S2, for each amplicon the minimum
sequencing depth value was never below 50×, except for NPM1 in cases AML#4, AML#7, AML#14
and AML#18.
3.2. Variant Calling, Filtering and Annotation
The main drawback of using MinION in variant analyses is its error rate. In our experience, data
from MS is affected by two kinds of errors, sporadic and recurrent, which require ad hoc filtering
strategies. Generally, sporadic errors are easily overcome by increasing the depth of coverage, but
reducing the sensitivity in reporting variants is required. For this reason, we set the minimum variant
allele frequency (VAF) to 10% for SNV and to 15% for INDELs in variant filtering [8,11]. On the
other hand, recurrent errors are easily detectable in more than one sample, but are characterized by a
homopolymeric genomic context and a high VAF value, which does not allow a reasonable threshold
to discriminate real variant from the sequencing error to be set.
Our past strategy to manage recurrent errors was to exclude affected positions from the analysis,
thereby reducing the breadth of coverage of the panel [11]. In this study, we developed a pipeline
to better manage the error effect in the final result, using the “Somatic Mutation Calling” of Varscan
(version 2.4.3) in order to compare the variants called in two NCs to each case. In our pipeline, when
the same variant is called both in the tumor and the NC, the significance of allele frequency difference is
calculated by Fisher’s Exact Test. SNV and INDEL files obtained from the previous variant calling step
were further filtered by VAF difference in NC and tumor (>10%), considering only variants featuring a
VAF > 7% in the NC (this cut-off value corresponded to the maximum mean sequencing error rate
calculated for the amplicons of our gene panel, see Table 1). A second filter was applied on p-values,
filtering off variants with a p-value > 0.01 (Filtering R script has been supplied in the File S2). Variant
calling, filtering and annotation produced a total of 34 variants, excluding FLT3 ITD. Among them,
ten were discordant and needed validation by SS. Overall, MS identified a false positive variant: an
insertion in TP53 gene at the end of a long homopolymer sequence (locus: chr17:7579470) (this type of
error has already been described [11]). The only false negative result from MS was a NPM1 mutation
(locus: chr5:170837543) due to a very low depth of coverage. On the other hand, S5S failed to detect two
small INDELs on the CEBPA gene (loci: chr19:33793152 and chr19:33793082). As reported in Table 2,
the VAFs of discordant variants detected on the CEBPA gene in loci chr19:33792277, chr19:33792729
(recurring 3 times) and chr19:33792731 (recurring twice) are below the SS sensitivity. Anyway, even if
we cannot certainly clarify this discrepancy, considering the good quality of the electropherograms
obtained, the recurrence of the variants and the known problematic nature of CEBPA sequencing, these
discordant variants could be reasonably considered as false positive. The specific error rate associated
to all MS variants identified with the pipeline developed was also determined and verified by visual
inspection of BAM files in both of the NCs sequenced. Overall, as reported in Table S3, the mean error
rate associated with these specific variants was significantly below the VAF cut-off of 7% except for
two INDELs and one SNV, harboring a higher error rate. A specific analysis of the variants detected in
the two NCs was also performed on CEBPA and TP53, the two genes entirely covered in our assay, in
order to identify SNVs and INDELs called with a VAF above 10% and 15%, respectively (Table S4).
The two NCs were analyzed in an independent manner, identifying a total of 12 SNVs and 41 INDELs;
the variants called only in a single NC had a VAF value close to the cut-off used for variant filtering
(10% and 15% for SNVs and INDELs, respectively). For these reasons, as currently these genomic
positions cannot be analysed in a robust manner, the final breadth of coverage of TP53 was 99.3%,
as compared to the previous MS performances [11], and for CEBPA it was 98.3%. These preliminary
results are intended to improve with the concomitant refinement of nanopore sequencing and the
dedicated analysis tools.
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Table 2. Description of variants identified by MinION sequencing and S5 sequencing. Only discordant variants were validated by Sanger sequencing.
Case Gene Locus Genotype CodingChange
Amino Acid
Change Type Function Length Exon
MinION
(VAF %)
S5 (VAF
%) Sanger
AML#1 IDH1 chr2:209113113 G/A c.394C p.R132 SNV missense 1 4 YES (48.9) YES (47.1) N/E
AML#2 FLT3 chr13:28608329 A/C c.1727T > G p.L576R SNV missense 1 14 YES (14.4) YES (8.3) N/E
AML#3 NPM1 chr5:170837547 -/TCTG c.859_860insTCTG p.W288fs*12 INDEL FrameshiftInsertion 4 11 YES (35.3) YES (54.5) N/E
AML#4 IDH1 chr2:209113113 G/A c.394C p.R132 SNV missense 1 4 YES (16.9) YES (14.4) N/E
AML#5 NPM1 chr5:170837547 -/TCTG c.859_860insTCTG p.W288fs*12 INDEL FrameshiftInsertion 4 11 YES (56.5) YES (45.8) N/E
IDH2 chr15:90631934 C/T c.419G p.R140 SNV missense 1 4 YES (32.4) YES (51.3) N/E
AML#7 NPM1 chr5:170837547 -/TCTG c.859_860insTCTG p.W288fs*12 INDEL FrameshiftInsertion 4 11 NO YES (58.5) YES
IDH2 chr15:90631934 C/A c.419G p.R140 SNV missense 1 4 YES (38.6) YES (53.5) N/E
CEBPA chr19:33792277 G/CT c.1044delinsAG p.S348fs INDEL FrameshiftInsertion 2 1 YES (15.4) NO NO
AML#8 NPM1 chr5:170837547 -/TCTG c.859_860insTCTG p.W288fs*12 INDEL FrameshiftInsertion 4 11 YES (33.3) YES (46.1) N/E
CEBPA chr19:33793152 -/G c.168dupC p.E57fs INDEL FrameshiftInsertion 1 1 YES (44.3) NO YES
AML#9 NPM1 chr5:170837547 -/TCTG c.859_860insTCTG p.W288fs*12 INDEL FrameshiftInsertion 4 11 YES (31.0) YES (55.9) N/E
CEBPA chr19:33792731 -/GCGGGT c.589_590insACCCGC p.H195_P196dup INDEL
Nonframe
shift
Insertion
6 1 NO YES (18.1) NO
AML#10 IDH2 chr15:90631934 C/T c.419G p.R140 SNV missense 1 4 YES (16.1) YES (12.1) N/E
AML#13 CEBPA chr19:33792387 -/CTGCGTCTCCACGTTGCGCTGCTTGGC c.933_934insGCCAAGCAGCGCAACGTGGAGACGCAG p.A303_Q311dup INDEL
Nonframe
shift
Insertion
27 1 YES (26.2) YES (38.9) N/E
CEBPA chr19:33793082 -/C c.238dupG p.D80fs INDEL
Frame
shift
Insertion
1 1 YES (30.4) NO YES
AML#14 CEBPA chr19:33792381 -/CTT c.939_940insAAG p.K313dup INDEL
Nonframe
shift
Insertion
3 1 YES (27.1) YES (48.7) N/E
CEBPA chr19:33793174 CG/C c.146delC p.P49fs INDEL FrameshiftDeletion 1 1 YES (42.1) YES (57.5) N/E
CEBPA chr19:33792729 G/A c.592C > T p.P198S SNV missense 1 1 NO YES (16.2) NO
AML#15 CEBPA chr19:33792729 G/A c.592C > T p.P198S SNV missense 1 1 NO YES (14.8) NO
AML#16 NPM1 chr5:170837545 -/TGCA c.861_862insTGCA p.W288fs*12 INDEL FrameshiftInsertion 4 11 YES (47.6) YES (46.6) N/E
IDH2 chr15:90631934 C/T c.419G p.R140 SNV missense 1 4 YES (60.7) YES (53.8) N/E
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Table 2. Cont.
Case Gene Locus Genotype CodingChange
Amino Acid
Change Type Function Length Exon
MinION
(VAF %)
S5 (VAF
%) Sanger
AML#17 NPM1 chr5:170837545 -/TGCA c.861_862insTGCA p.W288fs*12 INDEL FrameshiftInsertion 4 11 YES (39.1) YES (57.6) N/E
FLT3 chr13:28592642 C/A c.2503G p.D835 SNV missense 1 20 YES (49.0) YES (50.0) N/E
AML#18 TP53 chr17:7577120 C/T c.818G > A p.R273H SNV missense 1 8 YES (78.5) YES (72.8) N/E
CEBPA chr19:33792729 G/A c.592C > T p.P198S SNV missense 1 1 NO YES (15.7) NO
AML#19 TP53 chr17:7577538 C/T c.743G > A p.R248Q SNV missense 1 7 YES (68.2) YES (63.1) N/E
AML#20 TP53 chr17:7577082 C/T c.856G > A p.E286K SNV missense 1 8 YES (73.1) YES (79.1) N/E
AML#21 TP53 chr17:7577094 G/A c.844C > T p.R282W SNV missense 1 8 YES (48.7) YES (49.1) N/E
TP53 chr17:7578475 G/C c.455C > G p.P152R SNV missense 1 5 YES (21.0) YES (11.5) N/E
CEBPA chr19:33792731 -/GCGGGT c.589_590insACCCGC p.H195_P196dup INDEL
Nonframe
shift
Insertion
6 1 NO YES (25.2) NO
AML#22 TP53 chr17:7578413 C/T c.517G > A p.V173M SNV missense 1 5 YES (18.1) YES (45.3) N/E
TP53 chr17:7579715 AG/A c.81del p.E28Kfs * 16 INDEL FrameshiftDeletion 1 3 YES (45.0) YES (41.8) N/E
Note that * in Amino Acid Change column is used to indicate a stop codon, according to the nomenclature recommendations of the Human Genome Variation Society (HGVS). SNV: single
nucleotide variant, INDEL: insertion/deletion, VAF: Variant Allele Frequency, N/E: not evaluated.
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3.3. Identification of the Acute Myeloid Leukemia Hotspot Mutations
We focused on the following AML hotspot mutations: NPM1 p.W288fs, FLT3 p.D835, IDH1 p.R132,
IDH2 p.R140 and p.R172. For all these variants there was an almost complete concordance between
data obtained from MS and S5S (Table 2). In our cohort of AML cases, we detected a total of 14 hotspot
mutations: seven carrying the NPM1 p.W288fs variant, one case with the FLT3 p.D835 variant, two
cases showing the IDH1 p.R132 variant and four cases carrying the IDH2 p.R140. The sole difference
between MinION and S5 results was found in case AML#7 for NPM1. As reported in the coverage
analysis (Figure 2) of the MinION data, almost all targets were well covered (>500×), excluding NPM1
that showed a general lower coverage. In particular, case AML#7 showed a depth of coverage on
NPM1 below 50×, that caused the failure to detect the mutation. However, despite the lowest coverage
observed in the MS analysis of the NPM1 gene, in all other AML cases the comparison between MS and
S5 not generated false positive or negative results related to NPM1 gene status, and MS results were
confirmed by S5S. We have not identified the cause of this state that does not appear to be related to the
amplicon size nor to the nucleotide sequence of the genomic region, but that could link to the nature
of multiple gene analysis. Further improvements are needed to overcome this issue by redesigning
and testing new primer sets or adopting alternative enrichment strategies (i.e., hybridization [26] or
Cas9 [27] methods).
Figure 2. Boxplot of MinION sequencing depth of coverage, calculated for each amplicon.
3.4. FLT3 Internal Tandem Duplications (ITD) Data Analysis
Using the Sniffles tool, since Varscan was not able to detect large INDELs, in total, nine patients
were identified as ITD positive (Figure S1). All ITDs (median length 48 bp min.–max 30–165 bps) were
detected from MS and were confirmed by a specific PCR assay [22]. Results from S5S, instead, returned
AML#4 as false negative (ITD was length 165 bps). In particular, the false negative resulting from the
S5 analysis could be due to the length of the insertion/duplication and then to the limit of the read
length of the NGS. Furthermore, in AML the size of FLT3 ITD is very variable.
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It is now known that longer FLT3 ITDs are associated with a higher FLT3 kinase activity and
worse outcome [28–30]; however, the detection of long ITD and the detection of ITDs in combination
with deletions remain challenging when performed by short-reads-based technologies [31]. MinION
data do not have this limit, and for this reason resulted more suitable for this purpose.
3.5. CEBPA Data Analysis
For AML#13 and AML#14 cases bearing two CEBPA mutations, each detected by MS, the reads
containing the two variants were extracted from the original bam files. Overall, comparing the reads
containing one or the other of the two CEBPA-detected variants, in both AML cases, most reads had
one of the two identified mutations (91.8% and 92.7%, respectively), whereas only a small fraction of
reads contained both of them (8.2% and 7.2%, respectively) (Figure 3).
Figure 3. Data analysis of CEBPA MinION Sequencing in AML#13 (A) and AML#14 (B). For both
cases a snapshot is shown of the filtered alignments, visualized with the IGV tool and supporting each
CEBPA variant detected (left) and the Venn diagram of the reads identifiers supporting them (right).
The black arrows indicate the specific variant supported in each filtered alignment; according to IGV
display options, insertions larger than 20 nucleotides are flagged in red (A), whereas smaller insertions
are indicated with a purple flag (A,B). As regards the Venn diagrams, for both cases, the identifiers of
the reads supporting each CEBPA mutation were retrieved from the corresponding filtered SAM files,
and visually compared to establish the number of reads supporting the variants detected and phase the
two CEBPA mutations.
This observation indicated that in these AML patients the two CEBPA mutations detected in each
case were predominantly located on different alleles; however, this cannot exclude the possibility that
they occurred in different cells. As regards the co-occurrence of both CEBPA mutations in a small
subset of reads, this circumstance must presumably be explained by MinION context-specific error,
frequently associated with homopolymer sequences, or in the case of larger insertions/duplications, the
detection of similar events in the flanking genomic regions, rather than by the GC content characteristic
of CEBPA [32]. Mutations in the CEBPA gene occur in 7–15% of all AML cases; the subgroup of biallelic
CEBPA mutations in AML patients has now been acknowledged as a definite entity in the recent World
Health Organization (WHO) classification, given its distinct biological and clinical features, as well as
its prognostic significance [1]. To date, conventional capillary sequencing has been the gold-standard
DNA sequencing technique [33].
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Because of the lack of appropriate coverage across the entire gene and of the high GC content
leading to suboptimal amplification efficiency, a poor coverage and read depth in this gene using NGS
has been reported [34,35]. Our analysis revealed that CEBPA gene sequencing by S5S generated false
positives whereas MS is more precise and also more concordant with SS results. Moreover, the ability
to generate long reads spanning the entire gene allows AML cases with biallelic CEBPA mutations
(Figure 3) to be easily highlighted and phased, as described in previous studies concerning other genes
or genomic rearrangements [36,37] without completely excluding the possibility that they may occur
in different leukemic cells, our results are also consistent with a milestone study focused on CEBPA
double mutations studied by cloning [33]. On the other hand, our analysis showed that CEBPA gene
sequencing performed by MS is associated with nanopore context-specific error, frequently associated
with homopolymeric sequences; this circumstance does not affect the integrity of the previously
described result.
4. Discussion
The identification of gene mutations in AML patients has become routine in molecular diagnostic
laboratories via a variety of techniques. Many gene panels with varying sizes were developed in the
last years with the aim of providing essential information for the prognostic definition and for the
therapeutic management of AML patients, and recently it was validated a 19-gene AML-targeted NGS
panel that could be a valid approach to obtain clinically relevant information [38]. All conventional NGS
approaches are affected by two main limits: a quite long turnaround time (TAT) reaching up to seven
days, and the read length. Our work shows that the long-reads nanopore sequencing approach for gene
mutation analysis in AML is feasible and potentially able to satisfy the need of reducing the TAT for NGS
analysis. Nowadays, it is known that the complete validation of NGS tests includes several topics, such
as the use of reference cell lines or materials for the evaluation of assay performance, the assessment
of sequencing metrics and the optimum number of samples for test validation. According to the
regulatory requirements of Clinical Laboratory Improvement Amendments for laboratory-developed
tests, the evaluation of accuracy, precision, analytical sensitivity/limits of detection, analytical specificity
and the use of sensitivity controls for the detection of targeted mutations at the lower limit of detection
(LLOD) need to be defined [39]. Recommendations for an analytical validation of NGS bioinformatics
pipelines to be used for clinical detection of gene variants are also available [40]. In our work we started
with a relatively small set of samples to evaluate the potential of MS in the context of AML molecular
analysis, especially in relation to specific genomic issues which are difficult to solve with conventional
NGS strategies. However, given the satisfactory results obtained, when the technology will be ready
for its use in the clinical context, a validation set will need to corroborate MinION performances.
In the last decade, Illumina and Ion Torrent sequencers have been extensively evaluated and validated
in the clinical setting, whereas MinION sequencer was launched in pre-release form in 2014 and
today is an appealing, new sequencing paradigm continuously improving in terms of analytical
performance [23,41]. Nowadays, Nanopore sequencing is still in its testing phase, even if an increasing
improvement in performance compared to the beginning has been widely documented. On the other
hand, conventional NGS technologies are extremely powerful, but they also have some drawbacks.
One major limitation is the generation of short reads. The sequencing of the long-repeated sequences
of the human genome may lead to misassemblies and gaps. In addition, large structural variations are
more challenging to detect and characterize, using short reads. Moreover, NGS methods based on
PCR enrichment show difficulties for GC-rich regions. The nanopore sequencing approach overcomes
these difficulties; this is a very important aspect especially in the context of AML, where FLT3 ITD and
CEBPA mutations detection by NGS is complicated. Another main advantage highlighted in our work
is that reliable and absolutely reproducible results regarding the mutational status of the FLT3, IDH1
and IDH2 genes, where mutations have an established therapeutic indication (midostaurin, enasidenib
and ivosidenib, respectively), can be obtained in a very short time, about 24 h from sample collection.
Genes 2019, 10, 1026 13 of 16
5. Conclusions
Reducing the TAT is crucial in AML management, as recently described in the Patel et al. study,
in which a custom platform designated as Ultra-rapid Reporting of GENomic Targets (URGENTseq)
is reported [42]. Through the NGS workflow optimization and innovative custom bioinformatics
pipeline, the platform allows the analysis of selected genes useful for diagnosis and treatment decisions
in hematologic malignancies within 48 h of specimen collection [42]. We propose a workflow that can
potentially enable laboratories equipped with only basic molecular biology techniques to perform
detailed targeted gene sequencing analysis in AML patients, shortening TAT and reducing costs
(minimal IT infrastructure for sequencing and data analysis: Windows/OSX/Linux operative systems,
16 GB RAM, i7 or Xenon with 4+ cores CPUs, 1 TB internal SSD storage unity, USB3 ports). In fact,
processing the sample in the immediate onset of the disease, the cost of the analysis is around USD 200.
Moreover, the MinION cost (USD 1000) could enable all basic molecular biology laboratories to perform
detailed targeted gene sequencing analysis in AML patients without renouncing the quality of the
results that, in the context of AML onset, is crucial to define the prognosis and treatment. Furthermore,
scalability is one of the emerging strengths of nanopore technology; in fact the platform can be
adapted for smaller, frequent and rapid sequencing runs using a single-use flowcell, delivering up to
1.8 Gb of data (https://nanoporetech.com/products/flongle). The preliminary results about sequencing
performances of our assay, together with the constant improvement of nanopore sequencing technology,
pave the way for its future application in AML diagnostics.
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